Tu1346 Efficacy and Safety of Novel Class of Acid Suppressants: P-Cab-Based Amoxicillin and Clarithromycin 1 Week Triple Therapy as First Line Eradication of H. pylori in Japan. A Multicenter Study

Sue, Soichiro; Arima, Isao; Kuwashima, Hirohumi; Sanga, Katuyuki; Oka, Hiroyuki; Ishii, Yuniba; Kanno, Masatomo; Terada, Masahiro; Iwata, Yuri; Inokuchi, Yasuhiro; Fukuchi, Takehide; Komatu, Kazuto; Naito, Makoto; Kawana, Ichiro; Okazaki, Hiroshi; Saito, Toshifumi; Kunishi, Yosuke; Ikeda, Akihiko; Iwase, Shigeru; Morimoto, Manabu; Takahashi, Daisuke; Kokawa, Atsushi; Satô, Takeshi; Kameta, Eri; Ishii, Yasuaki; Kaneko, Hiroaki; Miwa, Hideaki; Sasaki, Tomohiko; Tamura, Toshihide; Kondo, Masaaki; Inamori, Masahiko; Shibata, Wataru; Maeda, Shin

doi:10.1016/s0016-5085(16)32971-7

Search citation statements

Order By: Relevance

Paper Sections

Select...

Helicobacter Pylori Treatment With Vonoprazan1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2016

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2016] using the vonoprazan-based triple regimen, a result comparable to previously reported rates [Murakami et al 2016]. Other recent reports from Japan have also indicated H. pylori eradication rates ranging from 88% to 94% with the government approved vonoprazan-based first-line triple therapy [Matsumoto et al 2016; Murayama et al 2016; Sue et al 2016].…”

Section: Helicobacter Pylori Treatment With Vonoprazansupporting

confidence: 77%

Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence

Akazawa

Fukuda

2016

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Stable suppression of gastric acid secretion is a crucial factor in Helicobacter pylori eradication. Vonoprazan is a potassium-competitive acid blocker recently approved for use in Japan. As vonoprazan has a long duration of action and causes rapid and strong inhibition of gastric acid secretion, it has gained clinical attention for treating erosive oesophagitis, peptic ulcers, and H. pylori infection. In this review, we discuss the recent knowledge regarding the safety and efficacy of vonoprazan, focusing on its use in H. pylori eradication. The latest literature and our clinical experience have shown that vonoprazan-based therapies have satisfactory eradication rates. Additionally, vonoprazan-based therapies are associated with similar rates of adverse events as standard triple therapies with conventional proton-pump inhibitors.

show abstract